v3.26.1
Restatement of Interim Financial Information (Unaudited) - Consolidated Statement of Operations (Details) - USD ($)
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2025
Dec. 31, 2024
Operating expenses:                
General and administrative expenses $ 6,794,042 $ 587,167 $ 2,268,762 $ 1,645,136 $ 9,062,804 $ 2,232,303 $ 14,766,607 $ 3,441,820
Research and development expenses 1,920,372 146,724 1,549,775 213,762 3,470,147 360,486 6,617,562 661,183
Other non-operating income (expense):                
Change in fair value of SAFE Notes (36,715,107) (495,351)   158,020     (39,834,049) (1,631,446)
Net loss $ (45,414,335) $ (1,220,296) $ (6,936,475) $ (1,689,843) $ (52,350,810) $ (2,910,139) $ (61,002,954) $ (5,713,369)
Basic weighted average shares outstanding of common stock (in shares) 23,434,266 13,189,817 14,057,349 5,484,637 17,391,203 8,676,304 25,332,277 10,037,251
Diluted weighted average shares outstanding of common stock (in shares) 23,434,266 13,189,817 14,057,349 5,484,637 17,391,203 8,676,304   10,037,251
Basic net loss per share of common stock (in dollars per share) $ (1.94) $ (0.09) $ (0.49) $ (0.31) $ (3.01) $ (0.33) $ (2.41) $ (0.57)
Diluted net loss per share of common stock (in dollars per share) $ (1.94) $ (0.09) $ (0.49) $ (0.31) $ (3.01) $ (0.33)   $ (0.57)
As Previously Reported                
Operating expenses:                
General and administrative expenses $ 6,700,416 $ 486,151 $ 2,718,780 $ 752,535 $ 9,419,196 $ 1,238,686    
Research and development expenses 2,104,021 219,478 780,517 135,930 2,884,538 355,408    
Other non-operating income (expense):                
Change in fair value of SAFE Notes (31,601,632) (1,248,279)   (1,251,721)        
Net loss $ (40,390,883) $ (1,944,963) $ (7,136,460) $ (2,129,151) $ (47,527,343) $ (4,074,114)    
Basic weighted average shares outstanding of common stock (in shares) 31,316,149 16,182,268 16,237,748 658,569 21,282,445 13,006,041    
Diluted weighted average shares outstanding of common stock (in shares) 31,316,149 16,182,268 16,237,748 658,569 21,282,445 13,006,041    
Basic net loss per share of common stock (in dollars per share) $ (1.29) $ (0.12) $ (0.44) $ (3.23) $ (2.23) $ (0.31)    
Diluted net loss per share of common stock (in dollars per share) $ (1.29) $ (0.12) $ (0.44) $ (3.23) $ (2.23) $ (0.31)    
Adjustment                
Operating expenses:                
General and administrative expenses $ 93,626 $ 101,016 $ (450,018) $ 892,601 $ (356,392) $ 993,617    
Research and development expenses (183,649) (72,754) 769,258 77,832 585,609 5,078    
Other non-operating income (expense):                
Change in fair value of SAFE Notes $ (5,113,475) 752,928   1,409,741        
Net loss   $ 724,667 $ 199,985 $ 439,308 $ (4,823,467) $ 1,163,975    
Basic weighted average shares outstanding of common stock (in shares) (7,881,883) (2,992,451) (2,180,399) 4,826,068 (3,891,242) (4,329,737)    
Diluted weighted average shares outstanding of common stock (in shares) (7,881,883) (2,992,451) (2,180,399) 4,826,068 (3,891,242) (4,329,737)    
Basic net loss per share of common stock (in dollars per share) $ (0.65) $ 0.03 $ (0.05) $ 2.92 $ (0.78) $ (0.02)    
Diluted net loss per share of common stock (in dollars per share) $ (0.65) $ 0.03 $ (0.05) $ 2.92 $ (0.78) $ (0.02)